Beijing Bohui Innovation Biotechnology Group Co. Ltd. Class A

Beijing Bohui Innovation Biotechnology Group Co. Ltd. Class A

SSZSE:300318
4.35
CNY
-0.04
(-0.91%)
-0.19EPS
4.27BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.16
0.14
0.69
0.5
0.54
0.76
0.77
0.91
0.87
0.97
1.28
1.04
1.01
1.01
Basic EPS, GAAP
0.08
0.05
0.03
0.03
0.05
0.08
- -
0.01
-0.39
-0.1
-0.03
0.01
-0.11
-0.1
Free Cash Flow per Basic Share
0.02
-0.04
0.14
0.05
-0.17
-0.17
-0.18
-0.14
-0.45
-0.15
-0.07
-0.28
-0.36
- -
Dividend per Share
0.02
0.02
0.01
- -
0.02
0.02
0.04
0.03
0.03
0.03
0.06
0.04
0.04
0.04
Book Value per Share
1.07
1.11
1.7
1.73
1.79
1.43
1.26
1.59
1.19
1.71
1.68
1.69
1.57
1.55
Tangible Book Value per Share
0.97
0.97
0.46
0.5
0.5
0.2
-0.02
-0.3
-0.28
0.32
0.29
0.22
0.13
0.11
Basic Weighted Avg Shares
653
734
392
814
816
819
820
816
817
817
817
818
817
817
Sales/Revenue/Turnover
107
101
269
404
444
622
628
739
715
796
1,045
852
825
822
Operating Margin (%)
42.38
21.74
2.74
13.6
7.62
9.58
9.25
5.59
-13.66
-11.37
6.64
8.46
0.84
-4.32
Depreciation Expense
5
8
29
39
49
68
73
90
108
109
113
104
99
- -
Net Income, GAAP
54
38
12
24
39
69
3
8
-322
-78
-25
9
-92
-83
Effective Tax Rate (%)
15.25
15.18
- -
2.99
52.82
27.55
78.97
1,390.93
- -
- -
53.51
56.41
- -
- -
Profit Margin (%)
50.77
37.77
4.42
5.84
8.76
11.16
0.4
1.02
-45.08
-9.86
-2.38
1.09
-11.15
-10.09
Working Capital
468
419
-260
-68
148
-144
-419
-917
-1,455
17
60
12
-104
-210
LT Debt
- -
- -
- -
- -
66
106
133
147
92
333
380
428
472
403
Total Equity
703
727
1,283
1,524
1,614
1,244
1,052
1,439
933
2,323
2,341
2,349
2,176
2,131
Return on Invested Capital (%)
7.2
4.67
- -
2.94
2.72
4.51
0.14
-2.4
- -
- -
0.5
0.47
- -
- -
Return on Capital (%)
6.55
4.77
- -
0.44
2.49
4.96
0.75
-23.3
- -
- -
-1.68
0.69
- -
- -
Return on Common Equity (%)
8.04
5.37
1.12
1.68
2.69
5.25
0.23
0.64
-28.33
-6.62
-1.8
0.67
-6.9
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
447
524
499
LT Borrowings
444
367
371
LT Finance Leases
37
35
32
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
817
817
817
Market Capitalization
4,779
3,415
4,272

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,481
1,512
1,567
Cash, Cash Equivalents & STI
143
114
136
Accounts Receivable, Net
104
112
128
Inventories
1,174
1,206
1,224
Total Current Liabilities
1,583
1,715
1,776
Payables & Accruals
- -
- -
- -
ST Debt
447
524
499
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.07%
21.53%
-7.37%
Free Cash Flow
-6.65%
80.53%
28.31%
Net Income, GAAP
-542.78%
-1,153.71%
-1,094.2%
Sales/Revenue/Turnover
13.66%
3.55%
-3.18%
Total Cash Common Dividend
44.89%
9.88%
-3.91%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
262
225
159
206
852
2025
202
202
- -
196
825
2026
190
206
231
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.01
- -
-0.02
0.01
2025
- -
-0.02
- -
-0.07
-0.11
2026
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Yan Jiang
Full Time Employees
2,170
Sector
Health technology
Industry
Biotechnology
Address
No. 9 Courtyard, Shengshengyuan Road Beijing BE China 102206
IPO Date
May 22, 2012
Business
Beijing Bohui Innovation Biotechnology Group Co., Ltd. operates as a high-tech biomedical enterprise, engaging in the research, development, manufacturing, distribution, and comprehensive after-sales support for diagnostic solutions and scientific instrumentation within China and globally. The company's portfolio encompasses advanced in-vitro diagnostic platforms, including fully automated nucleic acid detection systems leveraging microfluidic technology, alongside sophisticated fluorescence immunoassay and trace element analysis instruments. Additionally, it provides a range of analytical instruments such as mass spectrometry platforms and purification systems, enhanced through strategic international acquisitions. Bohui Group further extends its reach into biopharmaceuticals, developing and producing blood products like albumin and immunoglobulins, as well as various vaccine products, with a recent joint venture securing clinical trial approval for an Hib Vaccine. Established in 2001 and headquartered in Beijing, China, the firm was listed on the Shenzhen Stock Exchange ChiNext in May 2012. The company recorded substantial growth, with revenues reaching RMB 1.8 billion in 2023, fueled by strong demand and increased exports.